MSH3 and colorectal cancer: ,11 Specifically, MSH3 becomes dysfunctional in 50% of colorectal cancers by a somatic loss-of-function mechanism from proinflammatory interleukin-6 (IL6)/JAK/STAT3 signaling and/or oxidative stress via nuclear-to-cytosolic shifting of MSH3.2